Please send us your submissions for Classifieds using the form below, this column.


Classified Positions Available

ST. PETER'S HOSPITAL, a member of St. Peter’s Health Partners, located in Albany, NY, is seeking a full time Addiction Medicine physician to join its established and respected team. The position provides inpatient addiction medicine (detoxification/rehabilitation) and medical management services in our 18 bed inpatient unit with midlevel provider support.  

Candidates should be board certified in IM/FP and possess at least one year of direct experience with addiction medicine. Certification in the administration of Suboxone is required. ASAM/ABAM certification is strongly preferred and will be required within one year of hire if not already obtained.  

The position offers a competitive salary and benefits package including: health/vision/dental, paid malpractice, 30 days paid leave annually with carry over and buy out options, CME allowance & dedicated time off, 403(b) and cash pension programs.

Albany is a medium sized city offering all the amenities of a larger city in a beautiful, scenic, and affordable setting. Albany has excellent year-round outdoor recreation, including great golf, water-sports, camping, hiking, and great skiing. Albany offers a wealth of cultural offerings and activities, including several renowned museums and theaters, fine dining, and a year-round events calendar of music and sporting events. Excellent public and private schools are available, as are affordable homes and reasonable taxes. Albany is a short drive from beautiful Saratoga Springs, the scenic Adirondack, Berkshire, and Catskill Mountains, and is part of New York’s Historic Hudson and Mohawk Valleys. Centrally located, Albany is less then three hours from New York City and Boston.

Find out more and apply online at

These are not  J-1 or H1-B opportunities

This form does not yet contain any fields.

    Member News

    Please send us your submissions for Member News using the form below, right column.


    « Amphetamines: Not Just for Kids Anymore | Main | Treating Tobacco Use Online Learning Module for Health Care Providers »

    Ottawa to tackle opioid abuse with tamper-resistance rules 

    The Globe and Mail

    The federal government is introducing new tamper-resistance rules for opioid painkillers aimed at reducing prescription-drug abuse.

    On Friday, Health Canada announced draft regulations that would require all oxycodone products to be “tamper-resistant” before they can be sold. Tamper-resistant refers to drugs that are difficult to crush, snort or inject as a way of preventing people from getting high. The new rules are designed to help combat the growing problem of opioid misuse and abuse in Canada, which has the world’s second-highest per capita consumption of the drugs, which include oxycodone, fentanyl and morphine.

    Prescription pill bottle containing oxycodone and acetaminophen are shown in this June 20, 2012 photo. The Canadian Press

    From morphine to ‘hillbilly heroin’

    “Prescription-drug abuse is a significant public-health and safety concern,” Health Minister Rona Ambrose said in a statement. “Adding tamper-resistant properties to drugs at high risk of abuse is an important component of our government’s comprehensive approach to fighting prescription-drug abuse.”

    The proposed rules include a three-year phase-in period to allow companies to reformulate products. If companies do not reformulate products in that time period, they will not be allowed to sell them in Canada.

    But prominent Canadian medical organizations and experts are concerned the government’s push toward tamper-resistance is deeply flawed. The scientific evidence defining tamper resistance and whether it actually works at reducing rates of abuse is still relatively new. And the regulations would apply only to one type of opioid, which could simply shift the problem elsewhere.

    The only way the government’s new rules will have any impact is if the tamper-resistance requirements are extended to all opioids, said Dr. Chris Simpson, president of the Canadian Medical Association.

    “If you create a deterrent for one drug, then people just move to other drugs that don’t have that technology,” he said in an interview.

    In its official submission to Health Canada last year on the proposed new rules, the Canadian Pharmacists Association urged the federal government not to single out a single drug category for tamper-resistance requirements, in order “to prevent drug abusers from switching to another” drug.

    And tamper-resistance targets only a subset of opioid users, namely those who abuse drugs by snorting, chewing or injecting.

    “That’s the only element that tamper resistance addresses,” said Phil Emberley, director of pharmacy innovation at the Canadian Pharmacists Association. “Those people that get large quantities of this drug and take it by mouth, tamper-resistance is not going to change that.”

    In addition to the new regulations, the federal government has also launched a national marketing campaign to help parents talk to their children about prescription-drug abuse and has set aside funds to address the problem, including $13.5-million over five years to help First Nations communities and $8-million for prescriber education programs and the development of a national monitoring and surveillance program.

    References (4)

    References allow you to track sources for this article, as well as articles that were written in response to this article.

    Reader Comments

    There are no comments for this journal entry. To create a new comment, use the form below.

    PostPost a New Comment

    Enter your information below to add a new comment.

    My response is on my own website »
    Author Email (optional):
    Author URL (optional):
    Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>